Gilead Sciences’ Phase 3 Study on Triple Negative Breast Cancer: A Potential Game-Changer?

Gilead Sciences ((GILD)), Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study.

Gilead Sciences is conducting a Phase 3 clinical study titled ‘A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy.’ The study aims to evaluate the effectiveness and safety of sacituzumab govitecan-hziy combined with pembrolizumab compared to the treatment of physician’s choice in patients with triple negative breast cancer that remains after surgery and pre-surgical treatment.

The intervention involves administering sacituzumab govitecan-hziy and pembrolizumab intravenously, targeting the remaining cancer cells post-surgery. The alternative treatment includes either pembrolizumab alone or in combination with capecitabine, offering a comparative approach to determine the most effective treatment.

This randomized, open-label study employs a parallel intervention model with no masking, focusing primarily on treatment. Participants are randomly assigned to receive either the experimental treatment or the physician’s choice treatment.

The study began on December 12, 2022, and is currently recruiting. The primary completion and estimated study completion dates are yet to be updated, with the last update submitted on August 13, 2025. These dates are crucial for tracking the study’s progress and anticipating results.

This study could significantly impact Gilead Sciences’ stock performance, as positive results may enhance investor confidence and position the company favorably against competitors in the oncology sector. The ongoing research underscores Gilead’s commitment to advancing cancer treatment options.

The study is ongoing, with further details available on the ClinicalTrials portal.